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Abstract
 
Antigen-specific CD4 T helper type 2 (Th2) cells play a pivotal role in the induction of allergic
asthma, but the mechanisms regulating their recruitment into the airways are unknown. Signal
transducer and activator of transcription factor (Stat)6 is a transcription factor essential for Th2
cell differentiation. Here we show that Stat6 also controls Th2 cell recruitment and effector
function in allergic inflammation in vivo. To isolate the role of Stat6 in regulating Th2 cell
trafficking and effector function from its role in Th2 cell differentiation, we used a murine
model of asthma in which in vitro–differentiated Stat6
 
1
 
/
 
1
 
 antigen-specific Th2 cells were
adoptively transferred into naive Stat6
 
2
 
/
 
2
 
 and Stat6
 
1
 
/
 
1
 
 mice followed by aerosol antigen chal-
lenge. We found that all of the features of asthma, including Th2 cell accumulation, Th2 and
eosinophil-active chemokine production, and airway eosinophilia, mucus production, and hy-
perresponsiveness seen in Stat6
 
1
 
/
 
1
 
 mice, were dramatically absent in Stat6
 
2
 
/
 
2
 
 mice that re-
ceived Stat6
 
1
 
/
 
1
 
 antigen-specific Th2 cells. Our findings establish Stat6 as essential for Th2 cell
trafficking and effector function and suggest that interruption of Stat6 signaling in resident cells
of the lung is a novel approach to asthma therapy.
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Introduction
 
Allergic asthma is a disease of airway inflammation associ-
ated with airway hyperresponsiveness (AHR),
 
1
 
 eosino-
philia, and increased mucus production in the lungs (1).
CD4
 
1
 
 Th2 cells are believed to play a critical role in con-
trolling the inflammation seen in asthma, as elevated levels
of IL-4 and IL-5 have been detected in bronchial biopsies,
bronchoalveolar lavage (BAL), and blood of allergic pa-
tients compared with normal individuals (2–4).
Murine models of pulmonary inflammation and AHR
have elegantly demonstrated that Th2 cells and the cyto-
kines they secrete are essential for the development of eosin-
ophilia and AHR (5–8), validating these observations in hu-
mans with allergic asthma. Adoptive transfer of effector Th2
cells into naive mice followed by exposure to inhaled anti-
gen induces the pathophysiological features of asthma, in-
cluding eosinophilic inflammation, mucus hypersecretion,
and AHR (9–11), demonstrating that these cells are fully ca-
pable of producing the asthma phenotype. Although it is
firmly established that Th2 cells are central to the pathogen-
esis of asthma, the molecular mechanisms controlling Th2
cell trafficking into the lung are unknown.
Signal transducer and activator of transcription factor
(Stat)6 is essential for the induction of IL-4– and IL-13–
mediated responses (12–14). Ligation of the IL-4R or IL-
13R results in the activation of Stat6 through the phosphor-
ylation by Janus kinase (JAK1 and JAK3; reference 15). In
vivo, T cells from Stat6-deficient (Stat6
 
2
 
/
 
2
 
) mice are un-
able to differentiate into Th2 cells in response to IL-4 or
IL-13, and B cells from these mice cannot undergo class
switching to IgE, suggesting that the Stat6 pathway is im-
portant for the allergic response (13, 14). In fact, pulmo-
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Abbreviations used in this paper: 
 
AHR, airway hyperresponsiveness;
BAL, bronchoalveolar lavage; CCR, CC chemokine receptor; MDC,
macrophage-derived chemokine; PAS, periodic acid-Schiff; RPA,
RNase protection assay; Stat, signal transducer and activation of transcrip-
tion; TARC, thymus- and activation-regulated chemokine; TCA, thy-
mus-derived chemotactic agent; VCAM, vascular cell adhesion molecule. 
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nary eosinophilia, AHR, and mucus production were
decreased in Stat6
 
2
 
/
 
2
 
 mice that were sensitized and chal-
lenged with OVA compared with their wild-type litter-
mates (16–18). Stat6
 
2
 
/
 
2
 
 mice also do not develop Th2 cy-
tokine– and allergen-specific IgE responses in this model,
indicating a critical role for Stat6 in mediating the allergic
airway response by inducing Th2 cell differentiation.
However, the marked defect in Th2 cell differentiation in
these mice has precluded these studies from addressing the
role of Stat6 in the trafficking and effector functions of Th2
cells in the allergic lung.
To understand the role of Stat6 in Th2 cell trafficking
and Th2 cell effector functions in vivo apart from its role in
Th2 differentiation, we adoptively transferred OVA-spe-
cific (Stat6
 
1
 
/
 
1
 
) Th2 cells into Stat6
 
2
 
/
 
2
 
 and Stat6
 
1
 
/
 
1
 
 mice
followed by OVA aerosol challenges. We found that the
ability of adoptively transferred Th2 cells to mediate the
asthma phenotype, including pulmonary eosinophilia, mu-
cus production, and AHR, was dependent on Stat6 expres-
sion in resident cells of the lung. Our results demonstrate a
novel role for Stat6 in the recruitment of Th2 cells and
eosinophils to the lung and the production of chemokines
active on these cells.
 
Materials and Methods
 
Mice.
 
DO11.10 mice transgenic for the TCR recognizing
OVA peptide 323–339 (pOVA
 
323–339
 
) were bred in our facility.
Stat6
 
2
 
/
 
2
 
 and wild-type Stat6
 
1
 
/
 
1
 
 mice on a Balb/c background
between 7 and 9 wk of age were obtained from The Jackson Lab-
oratory.
 
Generation of Th2 Cells.
 
CD4 T cells were isolated from
spleen and pooled LNs of D011.10 mice using Dynal beads. Puri-
fied CD4 T cells (2
 
 3 
 
10
 
5 
 
cells/ml) were activated in the presence
of 50 
 
m
 
g/ml mitomycin c–treated Balb/c splenocytes (2
 
 3 
 
10
 
6
 
cells/ml), 1 
 
m
 
g/ml pOVA
 
323–339
 
, 1,000 U/ml IL-4 (PeproTech),
anti–IFN-
 
g
 
 (R46A2) at inhibitory concentrations, and anti-
CD28 at stimulatory concentrations in 24-well plates. On days 3
and 5, cells were fed with 5–10 U/ml of IL-2 (PeproTech). At
the time of transfer, an aliquot of cells was retained for restimula-
tion. 1 
 
3
 
 10
 
6
 
 CD4 cells and 2
 
 3 
 
10
 
6
 
 freshly isolated mitomycin
c–treated Balb/c splenocytes were cultured with 1 
 
m
 
g/ml
pOVA
 
323–339
 
. Supernatants were collected at 48 h after stimula-
tion for cytokine ELISA. Th2 cells produced between 50 and 150
ng/ml of IL-4, 50 and 150 ng/ml of IL-5, 30 and 75 ng/ml of IL-
13, and very low levels of IFN-
 
g
 
.
 
Transfer of Th2 Cells and OVA Challenges.
 
Th2 cells were
harvested on days 5 and 6, washed twice in PBS, and 5
 
 3
 
 10
 
6 
 
cells
were injected intravenously into Stat6
 
1
 
/
 
1
 
 or Stat6
 
2
 
/
 
2
 
 Balb/c re-
cipients. After transfer, mice were challenged seven times (for 20
min daily) with a 5% OVA solution or PBS (control mice) using a
nebulizer (Pulmo Aide; DeVil Biss).
 
Determination of AHR.
 
AHR was measured in Stat6
 
1
 
/
 
1
 
 and
Stat6
 
2
 
/
 
2
 
 mice after six OVA or PBS aerosol challenges by re-
cording respiratory pressure curves using whole body plethysmo-
graph (Buxco; EMKA Technologies) in response to inhaled
methacholine (Sigma-Aldrich) at concentrations ranging from 3
to 50 mg/ml. AHR was expressed in enhanced pause (
 
P
 
enh
 
), a
calculated value that correlates with measurement of airway resis-
tance, impedance, and intrapleural pressure in the same mouse.
 
BAL and LN Isolation.
 
BAL was performed 
 
z
 
18 h after the
last aerosol challenge with six 0.5-ml aliquots of PBS containing
0.6 mM EDTA. BAL cytokine levels were measured using the
lavage fluid recovered from the first 1 ml of instilled PBS/EDTA
to avoid overdilution of the BAL fluid components. Recovered
live cells (Trypan blue exclusion) were enumerated using a
hemocytometer. Cell differential counts were determined on
DiffQuik-stained cytocentrifuge preparations of cells recovered
from BAL. Single cell suspensions of paratracheal LN cells were
prepared for flow cytometry analysis.
 
Histology, Northern Blot Analysis, and RNase Protection Assays.
 
Lungs were harvested after the BAL and inflation was fixed to to-
tal lung capacity in 10% formalin. Formalin-preserved lung tissue
was stained with hematoxylin and eosin or diastase periodic acid-
Schiff (PAS). The severity of inflammation was graded semiquan-
titatively for the following features: eosinophils, lymphocytes,
granulomatous inflammation, giant cells, macrophages, and mu-
cous cells. Each of these features was graded on a scale of 0 to 4
where 0 
 
5 
 
none, 1 
 
5 
 
mild, 2 
 
5 
 
moderate, 3 
 
5 
 
severe, and 4 
 
5
 
very severe based on the severity and extent of the features in the
histological sections. Randomized and blinded slides were graded
by F. Green. For RNA isolation, lungs were snap frozen in liquid
nitrogen and lysed in guanidium hydrochloride followed by pel-
leting through a CsCl
 
2
 
 gradient. For the RNase protection assay
(RPA), 5 
 
m
 
g of RNA from each sample was analyzed using Ri-
boquant RPA kits mCK-1 (BD PharMingen). For Northern blot
analysis, 20 
 
m
 
g of RNA from each sample was analyzed as de-
scribed previously (19). Murine cDNA probes for macrophage-
derived chemokine (MDC), thymus- and activation-regulated
chemokine (TARC) (ABCD-2), and thymus-derived chemotac-
tic agent (TCA)-3 were gifts from P. Gray (ICOS Corp., Bethell,
WA), C. Schaniel (Basel Institute of Immunology, Boston, MA),
and M. Dorf (Harvard Medical School, Boston, MA), respec-
tively.
 
Cytokine Assays.
 
Levels of IL-4, IL-5, and IFN-
 
g
 
 were mea-
sured by ELISA (Endogen) as were levels of IL-13 (R&D Sys-
tems).
 
Flow Cytometry.
 
Cell suspensions from the BAL and LNs
were analyzed by three-color flow cytometry on a FACScan™
(Becton Dickinson) cytofluorimeter as described previously (19).
Commercial conjugated antibodies used for cell staining in-
cluded: anti-CD4–PE; anti-CD3–FITC; anti-CD8–CyChrome;
anti-CD25–FITC; anti-B220–PE (BD PharMingen); and anti-
KJ1-26–FITC (Caltag Biochemicals), an antibody specific for the
transgenic TCR in the DO11.10 mice.
 
Statistical Analysis.
 
Student’s 
 
t
 
 test (unpaired, two-tailed) was
used to calculate significance levels for all measurements except
lung histology scores, which were compared using Fisher’s exact
test. 
 
P 
 
,
 
 0.05 was considered statistically significant.
 
Results
 
Stat6 Is Essential for Airway Eosinophilic Inflammation after
Transfer of Stat6
 
1
 
/
 
1
 
 Th2 Cells and Aerosol Challenge.
 
Stud-
ies using Stat6
 
2
 
/
 
2
 
 mice have revealed that Stat6 plays an es-
sential role in the development of allergic inflammation
(16–18). Since Stat6
 
2
 
/
 
2
 
 mice do not develop Th2 cells, the
role of Stat6 in Th2 cell trafficking could not be assessed in
these experiments. We generated OVA-specific Stat6
 
1
 
/
 
1
 
Th2 cells from DO11.10 mice in vitro using OVA
peptide
 
323–339
 
, IL-4, and anti–IFN-
 
g
 
. We confirmed that
these cells were functional Th2 cells by their preferential 
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secretion of high levels of IL-4, IL-5, and IL-13 and very
low levels of IFN-
 
g
 
. To determine if Stat6 is involved in
trafficking of Th2 cells into the lung, we transferred OVA-
specific Stat6
 
1
 
/
 
1
 
 Th2 cells into Stat6
 
1
 
/
 
1
 
 and Stat6
 
2
 
/
 
2
 
 mice
by tail vein injection followed by aerosol challenges with
OVA or PBS. After adoptive transfer and aerosol OVA
challenge, the total number of cells recovered from the
BAL of Stat6
 
2
 
/
 
2
 
 mice was significantly reduced compared
with cells recovered from the BAL of Stat6
 
1
 
/
 
1
 
 mice (1.6 
 
3
 
10
 
6
 
 vs. 5.9 
 
3 
 
10
 
6 
 
cells; Fig. 1 a). As expected, 50–60% of
BAL cells in OVA-challenged Stat6
 
1
 
/
 
1
 
 (OVA-Stat6
 
1
 
/
 
1
 
)
mice were eosinophils. In striking contrast, only 1–2% of
BAL cells in OVA-Stat6
 
2
 
/
 
2
 
 mice were eosinophils (Fig. 1
a). The effect of Stat6 on the accumulation of other cell
types was more modest with OVA-Stat6
 
2
 
/
 
2
 
 mice having a
50% reduction in lymphocytes, a 30% reduction in mono-
cytes, and no significant differences in the number of neu-
trophils compared with OVA-Stat6
 
1
 
/
 
1
 
 mice. The few cells
recovered from the BAL of PBS-challenged Stat6
 
1
 
/
 
1 and
Stat62/2 mice were almost entirely macrophages (96–99%;
Fig. 1 a). Thus, adoptive transfer of Stat61/1 Th2 cells was
insufficient to recruit eosinophils into the BAL in Stat62/2
Figure 1. Attenuated eosinophilic
airway inflammation and mucus cell
production in Stat62/2 mice after
Th2 cell transfer and aerosol OVA
challenge. (a) BAL cell counts.
OVA-specific Stat61/1 Th2 cells
were transferred intravenously into
Stat61/1 and Stat62/2 mice and ex-
posed to daily challenges with aero-
solized OVA or PBS for 7 d. 18 h
after the last OVA challenge, leuko-
cytes were recovered from the BAL
and total and differential counts were
performed. Data represent mean
number of BAL cells (6 SEM; n =
10 for OVA-Stat61/1 and OVA-
Stat62/2 mice; n 5 3 for PBS-
Stat61/1 and PBS-Stat62/2 mice).
*P  , 0.0001; **P 5 0.0003; and
***P  5 0.02 in OVA-Stat61/1 versus
OVA-Stat62/2 mice. (b) Hematoxylin
and eosin (i and ii) and PAS (iii and
iv) stained formalin-fixed lung sections
isolated from Stat61/1 (i and iii) and
Stat62/2 mice (ii and iv) after transfer
of OVA-specific Th2 cell and aero-
sol OVA challenge described above.
(i) Stat61/1. Characteristic intense
peribronchial inflammatory cell infil-
trate comprised of lymphocytes and
eosinophils. Enlarged multinucle-
ated giant cells are seen within the
inflammation and the alveolar spaces.
In the peribronchial location, they
are loosely organized into a granu-
loma. (ii) Stat62/2. By contrast,
Stat62/2 mice show a marked atten-
uated inflammatory response around
the airways with notable and marked
decreases in eosinophils. There is al-
most complete absence of multinu-
cleated giant cells and granulomas.
(iii and iv) PAS staining of lung sec-
tions revealed characteristic mucin
staining in bronchial epithelium (ar-
row) of Stat61/1 (iii) mice, which is
almost completely absent in Stat62/2
mice (iv). Similarly treated PBS-
challenged Stat61/1 and Stat62/2
had no pulmonary inflammation or
mucus production (data not shown).
Note presence of subepithelial eo-
sinophils (arrowheads) in Stat61/1
(iii) but not Stat62/2 (iv) mice. Orig-
inal magnifications: (i and ii) 3125;
(iii and iv) 3600.1090 Stat6-dependent Th2 Cell Trafficking and Chemokine Production
mice after aeroallergen challenge, indicating that Stat6 sig-
naling in the lung is necessary for eosinophil recruitment.
Airway Eosinophilic Inflammation and Goblet Cell Mucus
Production Are Reduced in the Lungs of Stat62/2 Mice. His-
topathologic examination of lung tissue revealed that the
cardinal features of allergic inflammation were absent in the
Stat62/2 mice after Th2 cell transfer and OVA challenge.
Semiquantitative analysis revealed OVA-Stat61/1 mice had
peribronchial and perivascular infiltrates consisting mainly
of eosinophils, lymphocytes, multinucleated giant cells, and
granulomas. In contrast, OVA-Stat62/2 mice had markedly
diminished eosinophil accumulation in these locations,
similar lymphocyte accumulation, and a virtual absence of
multinucleated giant cells and granulomas (Table I). Simi-
larly, OVA-challenged Stat61/1 mice had many cells in the
airway epithelium that stained positive for mucus (Fig. 1 b,
iii). In contrast, very few cells were positive for mucus pro-
duction in OVA-Stat62/2 mice (Fig. 1 b, iv, and Table I),
which was similar to what we detected in the PBS-treated
controls (data not shown). Our data reveal a critical role for
Stat6 signaling in mediating the ability of Th2 cells to in-
duce eosinophilic inflammation, multinucleated giant cell
and granuloma formation, and mucus production in the
lungs of antigen-challenged mice in vivo.
Antigen-induced AHR Is Decreased in Stat62/2 Mice.
The physiology of asthma is characterized by AHR which
is also regulated by Th2 cells. OVA-Stat61/1 mice devel-
oped significant increases in AHR at 6.25 and 12.5 mg/ml
of methacholine, whereas OVA-Stat62/2 mice had no sig-
nificant increases in AHR over PBS-challenged Stat61/1
and Stat62/2 mice (Fig. 2). At higher doses of methacho-
line, increases in AHR were seen in OVA-Stat62/2 mice
compared with the PBS-challenged mice but the magni-
tude was lower than seen in the OVA-challenged Stat61/1
mice (Fig. 2). Thus, Stat6 expression in the resident cells of
the lung is also required for the induction of antigen-
induced AHR by Th2 cells in allergic inflammation.
OVA-specific Th2 Cells Are Markedly Decreased in the BAL
of OVA-Stat62/2 Mice. To determine if the failure of
transferred Th2 cells to mediate the asthma phenotype in
Stat62/2 mice resulted from an inability of these cells to
traffic to the airways, we analyzed the recruitment of trans-
ferred OVA-specific CD41 cells into the BAL and paratra-
cheal LNs. Aerosol OVA challenge resulted in a large influx
of lymphocytes into the BAL of OVA-Stat61/1 mice (1.2 3
106 cells), while PBS-challenged Stat61/1 mice had essen-
tially no lymphocytes in the BAL (Fig. 1 a). Of the lympho-
cytes recovered from the BAL of OVA-Stat61/1 mice, 46%
of the cells were CD41 (56 3 104 cells) and 16% (19 3 104
cells) were OVA-specific (Fig. 3, a and b). In striking con-
trast, 18% of the BAL lymphocytes in OVA-Stat62/2 mice
were CD41 (12 3 104 cells) and only 1.7% (1.1 3 104 cells)
were OVA-specific (Fig 3, a and b). The BAL of OVA-
Stat61/1  mice had an increased percentage of activated
CD41 (CD251) cells (8.0 vs. 3%) and a decrease in the per-
centage of B cells (B2201) (9.1 vs. 12%) and CD81 cells (14
vs. 23%) compared with OVA-Stat62/2 mice (Table II).
In paratracheal LNs, the total number of cells obtained
from both OVA-Stat61/1  and OVA-Stat62/2  mice was
highly increased compared with their PBS-challenged
Table I. Histopathologic Features in Lungs of OVA-Stat61/1 and OVA-Stat62/2 Mice after Adoptive Transfer of Th2 Cells
Eosinophils in 
Venules Bronchi Alveoli Giant cells Granulomas Mucous cells
OVA-Stat61/1 31 31 23 1 23 1
OVA-Stat62/2 11 11 00 0 1
P , 0.001 P , 0.001 P , 0.001 P , 0.001 P , 0.001 P , 0.001
OVA-specific Th2 cells were transferred into Stat61/1 and Stat62/2 mice and exposed to daily aerosol OVA challenges for 7 d. 18 h after the last
challenge, lungs were harvested, formalin fixed, and stained with hematoxylin and eosin or diastase PAS. The extent of the inflammatory cell infiltrate
was graded in a randomized and blinded fashion on a scale of 0 to 4. Data represent the average of 10 mice per group.
Figure 2. Stat62/2 mice have attenuated AHR after transfer of Th2
cells and OVA challenge. Airway reactivity to increasing concentrations
of methacholine was measured in OVA-Stat61/1 (n 5 8), OVA-Stat62/2
(n 5 8), PBS-Stat61/1 (n 5 4), and PBS-Stat62/2 (n 5 4) mice. Data rep-
resent mean Penh values (6 SEM). *P , 0.001 in OVA-Stat61/1 versus
OVA-Stat62/2 mice.1091 Mathew et al.
counterparts (Fig. 3 c), and compared with OVA-chal-
lenged mice without adoptive transfer (data not shown).
The percentage of CD41 cells in the LNs of Stat62/2 was
increased (42 vs. 30%), whereas the percentage of OVA-
specific T cells was decreased (0.3 vs. 1%) compared with
OVA-Stat61/1 mice (Fig. 3 d). There were no significant
differences between B cells and CD81 cell populations in
the LNs of the two groups (Table II). These data demon-
strate that despite evidence of antigen activation of trans-
ferred Th2 cells in the paratracheal LNs, trafficking of
transferred OVA-specific Th2 cells to the airways of
Stat62/2 mice was dramatically impaired.
Figure 3. Decreased recruitment of OVA-
specific Th2 cells in the BAL despite activation
in paratracheal LNs of Stat62/2 mice. (a and b)
Decreased OVA-specific CD41 cells in the
BAL of OVA-Stat62/2 mice. FACS® analysis
was performed on BAL cells isolated from mice
described above. Cells were stained with anti-
CD4 and KJ1-26 (OVA-TCR specific) anti-
bodies. (a) Percentage of CD4 and OVA-spe-
cific CD4 cells in the BAL of Stat61/1 and
Stat62/2 mice. *P , 0.0001 in OVA-Stat61/1
versus OVA-Stat62/2 mice. (b) Total number
of OVA-specific cells in the BAL = (% KJ1 cells
in the lymphocyte gate) 3 (total number of
lymphocytes calculated by differential counts).
*P  , 0.0001 in OVA-Stat61/1 versus OVA-
Stat62/2 mice. (c and d) Analysis of paratracheal
LNs of OVA- and PBS-challenged Stat61/1and
Stat62/2 mice after Th2 cell transfers. (c) Total
LN cells recovered from paratracheal LNs (n =
10 for OVA-Stat61/1 and OVA-Stat62/2 mice;
n  = 3 for PBS-Stat61/1 and PBS-Stat62/2
mice).  *P  , 0.0001 in OVA-Stat61/1 versus
PBS-Stat61/1 mice and OVA-Stat62/2 versus
PBS-Stat62/2 mice. (d) Percentage of CD4 and
OVA-specific cells in paratracheal LNs (mean of
five mice/group, representative of two experi-
ments). There were too few CD41 cells in the
BAL of PBS-Stat61/1 and PBS-Stat62/2 mice
for FACS® analysis. *P = 0.004 in Stat61/1 ver-
sus Stat62/2 mice; **P , 0.0001 in Stat61/1
versus Stat62/2 mice. 
Table II. Phenotype of BAL and LN Lymphocytes in OVA-Stat61/1 and OVA-Stat62/2 Mice after Adoptive Transfer of Th2 Cells
Percentage of cells in lymphocyte gate
Source of cells B2201 CD31 CD41 CD41CD251 CD81
OVA-Stat61/1 BAL 9 69 49 8 14
OVA-Stat62/2 BAL 12 50 20 3 23
P value NS P , 0.001 P , 0.001 P , 0.001 P , 0.01
OVA-Stat61/1 Draining LNs 23 75 46 3 22
OVA-Stat62/2 Draining LNs 21 74 55 3 18
P value NS NS P , 0.001 NS P 5 0.02
OVA-specific Stat61/1 Th2 cells were transferred into Stat61/1 and Stat62/2 mice followed by daily OVA aerosol challenges for 7 d. FACS®
analysis was performed on single cell suspensions of paratracheal LNs and BAL cells with the indicated antibodies. Values represent mean percentage
of cells in the lymphocyte gate for the individual mice (n 5 5 mice per group). Data are representative of two independent experiments. Similarly
treated PBS-challenged mice had too few CD41 T cells in the BAL and paratracheal LN cells for these studies.1092 Stat6-dependent Th2 Cell Trafficking and Chemokine Production
Allergen-induced BAL and Lung Cytokine Profile in Stat61/1
and Stat62/2 Mice. As Th2 cell cytokines are important
in regulating allergic inflammation, we determined levels of
IL-4, IL-5, and IL-13 mRNA in the lung and protein in
the BAL. Increased levels of IL-13 mRNA were detected
in the lungs of OVA-Stat61/1 mice, but not in the lungs of
the other groups (Fig. 4 a). Levels of IFN-g and IL-15
were detected in all groups with no elevations in antigen-
challenged mice. Elevated levels of IL-4 were detected in
the BAL of OVA-challenged mice compared with PBS-
challenged controls with no differences between antigen-
challenged Stat61/1 and Stat62/2 mice (Fig. 4 b). Levels of
IL-5 were surprisingly higher in OVA-Stat62/2 compared
with Stat61/1 mice (307 vs. 80 pg/ml). We speculate that
this difference results from the increased consumption of
IL-5 in the BAL of Stat61/1 mice secondary to the massive
Figure 4. Cytokine levels in the lung
and BAL of Stat61/1 and Stat62/2 mice.
(a) Cytokine mRNA expression was de-
termined by RPA analysis. Each lane
represents a single mouse. Levels of IL-4
(b), IL-5 (c), and IL-13 (d) were mea-
sured in the BAL of OVA- and PBS-
challenged Stat61/1 and Stat62/2 mice
by ELISA. Data are presented as mean
cytokine level (6 SEM; n 5 5 mice for
IL-4 and IL-5; n 5 10 for IL-13; n 5 3
for all PBS-challenged controls). *P 5
0.004 in OVA-Stat61/1  versus PBS-
Stat61/1 mice; **P 5 0.0002 in OVA-
Stat61/1 versus OVA-Stat62/2 mice;
and  P  5 0.001 in OVA-Stat62/2 versus
PBS-Stat62/2 mice. No significant dif-
ferences were detected in IL-13 levels.
Figure 5. Chemokine induction in the lungs of OVA-
and PBS-challenged Stat61/1 and Stat62/2 mice.
Chemokine mRNA expression was determined by North-
ern blot analysis. Each lane contains RNA from a different
mouse. Blots were sequentially hybridized with the cDNA
probes for the indicated chemokine and glyceraldehyde
3-phosphate dehydrogenase (GAPDH) as a control for
RNA loading. Blots were exposed for 72 h except for
TCA-3, which was exposed for 2 wk.1093 Mathew et al.
influx of pulmonary eosinophilia which is absent in the
BAL of Stat62/2 mice. In contrast to the RNA data, we
detected no significant differences in IL-13 protein levels in
the BAL of OVA- and PBS-challenged Stat61/1 and
Stat62/2 mice (Fig. 4 d). The difference in IL-13 profile in
BAL and lung that we observed may reflect differential reg-
ulation of cytokine synthesis in these two compartments of
the respiratory tract. In addition, no significant differences
in IFN-g levels were detected between the groups (data
not shown). Since the primary source of IL-4, IL-5, and
IL-13 is likely to be Th2 cells, the results indicate that the
very small percentage of OVA-specific T cells that were re-
cruited to the BAL of Stat62/2 mice were functional.
Differential Chemokine Gene Expression in the Lungs of
Stat61/1 and Stat62/2 Mice. The predominant chemokine
receptor expressed on eosinophils is CC chemokine recep-
tor (CCR)3 (20), whereas Th2 cells express CCR3,
CCR4, and CCR8 (21). We found highly elevated levels
of the CCR3 agonists eotaxin (CCL11) and eotaxin-2
(CCL24), and the CCR4 agonists MDC (CCL22) and
TARC (ABCD-2/CCL17) in the lungs of OVA-Stat61/1
mice compared with all other groups (Fig. 5). Our analysis
also revealed that expression of the CCR8 agonist, TCA-3
(I-309/CCL1), was markedly increased in the lungs of
OVA-Stat61/1 mice with lower expression in the lungs of
OVA-Stat62/2 mice. TCA-3 is a chemokine secreted by
activated T cells, preferentially of the Th2 type (22, 23).
The very faint levels of TCA-3 detected in OVA-Stat62/2
mice may simply reflect the decreased numbers of activated
T cells found in the lungs of the Stat62/2 mice. In contrast
to the expression of these “Th2-type” chemokines, the ex-
pression of IP-10, an IFN-g–inducible Th1-type chemo-
kine active on Th1 cells, was significantly elevated in OVA-
Stat62/2 mice compared with PBS-challenged controls.
These results demonstrate that Stat6 is essential for the in-
duction of chemokines critical for eosinophil and Th2 cell
recruitment to the allergic lung.
Discussion
Using an adoptive transfer model, we have demonstrated
that recruitment of antigen-specific Th2 cells to the airways
is Stat6 dependent. The reduction in Th2 cell accumula-
tion in the airways of OVA-Stat62/2 mice was accompa-
nied by a dramatic decrease in eosinophilia, goblet cell mu-
cus production, and AHR. The expression of key
chemokines implicated in Th2 cell and eosinophil traffick-
ing, such as eotaxin, eotaxin-2, TCA-3, TARC, and
MDC, was markedly attenuated in the lungs of OVA-
Stat62/2 mice. Therefore, our data demonstrate that in ad-
dition to its well-established role in Th2 cell differentiation,
Stat6 plays an important role in Th2 cell recruitment, Th2
type chemokine expression, and Th2 cell effector function
in vivo.
Airway eosinophilia is one of the characteristic features
of asthma that was absent in the OVA-Stat62/2 mice de-
spite the adoptive transfer of functional Th2 cells. Eosino-
phils migrate from the vasculature into different compart-
ments of the allergic lung where they damage the airway
epithelial cells that line the respiratory tract (24, 25). IL-5
has been clearly defined as the critical factor needed for the
differentiation and activation of eosinophils (26). Previous
studies have shown that eosinophilia is markedly dimin-
ished in Stat62/2 mice that have been sensitized and chal-
lenged with OVA. In one study, reconstitution of Stat62/2
mice with IL-5 during OVA challenge resulted in a marked
increase in eosinophilia, highlighting the importance of
IL-5 in this process (18). However, in our study eosinophilia
was dramatically decreased in the BAL and lungs despite el-
evated levels of IL-5 in the BAL of antigen-challenged
Stat62/2 mice, demonstrating that Stat6-dependent factors
are necessary to recruit eosinophils in response to Th2 cy-
tokines.
Secretion of mucus glycoproteins from the goblet cells
of the airway epithelium is another characteristic feature of
the asthma phenotype (1). We found that this feature of
asthma was also absent in Stat62/2 mice after OVA-specific
Th2 cell transfer and OVA challenge. The regulation of
mucus hypersecretion is under the control of Th2 cyto-
kines (1). In fact, overexpression of IL-4 in transgenic mice
induces increased mucus cell production and MUC 5 gene
expression from the epithelium (27). However, despite
comparably elevated levels of IL-4 in the BAL of OVA-
Stat62/2 and OVA-Stat61/1 mice, mucus hypersecretion
was absent in the lungs of OVA-Stat62/2 mice. Therefore,
our data suggest that in addition to its requirement for IL-4
production, Stat6 signaling is required for the airway epi-
thelium to respond to IL-4 with increased mucus produc-
tion.
Histopathological analysis also revealed a dramatic de-
crease in pulmonary granuloma and multinucleated giant
cell formation after adoptive transfer and OVA challenge in
Stat62/2 mice. Granulomatous inflammation has been de-
scribed in this murine model and likely represents a patho-
logical response to inhaled protein antigen. Little is known
about the molecular signals that regulate giant cell and
granuloma formation, although it has been reported that
IL-4 can induce giant cell formation from macrophages in
vitro (28). Our data indicate that Stat6 signaling is necessary
for the formation of giant cells and granulomas in this in
vivo model.
AHR is the third hallmark of asthma induced by the
Th2-type inflammation in the airways (1) that was absent
in the OVA-Stat62/2 mice. Although the precise mecha-
nism is poorly understood, recent studies suggest an impor-
tant role for Th2 cytokines, such as IL-4, IL-5, and IL-13
in AHR (1). Genetic deficiency or neutralization of each of
these cytokines diminished antigen-induced AHR in vivo,
whereas overexpression of IL-5 and IL-13 resulted in in-
creased AHR at baseline (5, 6, 29, 30). In fact, in a study
mentioned above, reconstitution of Stat62/2 mice with IL-5
during OVA challenge resulted in a marked increase in
AHR (18). In our studies, adoptive transfer of Th2 cells
into OVA-Stat62/2 mice failed to induce AHR despite el-
evated levels of IL-4 and IL-5 in the BAL. This finding
could be explained either by the failure of the airway epi-1094 Stat6-dependent Th2 Cell Trafficking and Chemokine Production
thelium to respond to IL-4 and IL-5 due to the lack of
Stat6 signaling or by decreased IL-13 levels as seen by RPA
in the OVA-STAT62/2 mice.
Th2 cells adoptively transferred into Stat62/2 mice failed
to traffic to the lung after OVA challenge. The molecular
mechanisms regulating Th2 cell trafficking to the allergic
lung are not known (31). Possible mechanisms regulating
Th2 cell trafficking include selective expression of adhesion
molecules and their counter ligands or selective expression
of chemokine receptors and Th2-active chemokines. Th1
cells express high levels of functional selectin ligands, such
as P-selectin ligand on their surface, which enable them to
be preferentially recruited to the sites of Th1 inflammation
(32–34). These cells also preferentially express CXC che-
mokine receptor (CXCR)3 and CCR5 and can be selec-
tively recruited by Th1-type chemokines, such as IP-10.
However, it is not clear whether Th2 cells express selective
adhesion molecules that facilitate their entry into the aller-
gic lung. The interaction between very late antigen 4 on
Th2 cells and vascular cell adhesion molecule (VCAM)-1
on the inflamed endothelium has been proposed as an at-
tractive candidate to mediate selective recruitment of Th2
cells in allergic inflammation as IL-4 upregulates VCAM-1
on endothelial cells (35). However, Stat6 is not involved in
the upregulation of VCAM-1 on pulmonary endothelial
cells, as VCAM-1 expression was increased in both Stat61/1
and Stat62/2 mice that were sensitized and challenged with
OVA, making differences in VCAM-1 expression an un-
likely explanation for our result (17). In the absence of a
specific molecular mechanism to explain Th2 cell–specific
recruitment, it has been proposed that Th2 cells passively
accumulate in allergic tissues as a result of the increased va-
sodilation seen during asthma (31).
However, Th2 cells preferentially express CCR3,
CCR4, and CCR8, and chemokines active on these recep-
tors are elevated in allergic inflammation, making them at-
tractive candidates to mediate Th2 cell–specific recruitment
(21). Inhibition or deletion of single chemokines or che-
mokine receptors (e.g., eotaxin, MDC, CCR3, CCR4)
have not abrogated Th2 cell recruitment in allergic pulmo-
nary inflammation (36–39). We hypothesized that multiple
and/or additional chemokines control Th2 cell trafficking
in this model, preserving trafficking of these cells in the ab-
sence of individual chemokines or their receptors. We
found a global deficiency of chemokines active on Th2
cells and eosinophils in Stat62/2 mice, which could explain
the marked reduction in Th2 cell and eosinophil trafficking
seen in our study. Therefore, our data provide the first evi-
dence that there are specific molecular signals that guide
Th2 cell trafficking and implicate Stat6-dependent chemo-
kines in this process.
We hypothesized that Th2 cytokines induce chemokine
production by resident parenchymal cells of the lung via
Stat6 signaling. IL-4 and IL-13 induce eotaxin-1, -2, and -3
expression in airway epithelial cells and endothelial cells
in vitro and in vivo (40–45), and IL-4 induction of eo-
taxin-1 gene expression was found to be Stat6 dependent
(46). IL-4 also induces MDC and TARC expression in
macrophages and respiratory epithelial cells and these
chemokines have been implicated in allergic inflammation
(37, 47). We have shown that eotaxin-1, eotaxin-2, MDC,
TARC, and TCA-3 expression in the allergic lung in vivo
is Stat6 dependent. Our finding that Stat6 signaling is nec-
essary for the production of all Th2 active chemokines is
consistent with there being functional Stat6 binding sites in
the promoters for these chemokines. While our study does
not establish the specific cellular source of Stat6-dependent
chemokine production, our adoptive transfer experiments
demonstrate that the expression of these chemokines re-
quires Stat6 signaling in resident cells of the lung. There-
fore, our data suggest that Stat6-inducible chemokines are
the molecular link between antigen-induced Th2 cell acti-
vation and Th2 cell and eosinophil recruitment in vivo.
The initial trafficking of Th2 cells to the airways in our
model is Stat6 independent since we were able to detect a
few OVA-specific Th2 cells in the BAL of Stat62/2 mice.
It is possible that these Th2 cells accumulate in the BAL
“passively” due to pulmonary vasodilation or that they are
actively recruited by Stat6-independent chemokine pro-
duction in the lungs after OVA aerosol challenges. The ul-
timate localization of Th2 effector cells into the lung, how-
ever, was markedly impaired in Stat62/2 mice, despite
evidence of antigen activation of transferred Th2 cells in
the paratracheal LNs of these mice. These results demon-
strate that trafficking of Th2 cells to the lung is an active
process dependent on Stat6 signaling in resident parenchy-
mal cells of the lung.
Our data support a model in which the initial aerosol
OVA challenge allows limited numbers of OVA-specific
Th2 cells to enter the lung in a Stat6-independent process.
Once in the lung these Th2 cells secrete cytokines, such as
IL-4 and IL-13, that activate resident pulmonary cells in a
Stat6-dependent manner to secrete chemokines active on
Th2 cells and eosinophils. These chemokines then amplify
the Th2 response by attracting large numbers of Th2 cell
and eosinophils. Recruited Th2 cells then induce mucus
production and AHR in a Stat6-dependent manner.
Overall our findings establish that Stat6 is a master regu-
lator of allergic inflammation. In addition to its known
ability to control Th2 cell generation through its activity in
lymphocytes, we have now shown that Stat6 also controls
Th2 cell trafficking through its activity in resident cells of
the lung.
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